<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34758687</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8387</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Expert review of proteomics</Title><ISOAbbreviation>Expert Rev Proteomics</ISOAbbreviation></Journal><ArticleTitle>Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>977</StartPage><EndPage>994</EndPage><MedlinePgn>977-994</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14789450.2021.2004890</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Proteomic analysis has contributed significantly to the study of the neurodegenerative disease amyotrophic lateral sclerosis (ALS). It has helped to define the pathological change common to nearly all cases, namely intracellular aggregates of phosphorylated TDP-43, shifting the focus of pathogenesis in ALS toward RNA biology. Proteomics has also uniquely underpinned the delineation of disease mechanisms in model systems and has been central to recent advances in human ALS biomarker development.</AbstractText><AbstractText Label="AREAS COVERED">The contribution of proteomics to understanding the cellular pathological changes, disease mechanisms, and biomarker development in ALS are covered.</AbstractText><AbstractText Label="EXPERT OPINION">Proteomics has delivered unique insights into the pathogenesis of ALS and advanced the goal of objective measurements of disease activity to improve therapeutic trials. Further developments in sensitivity and quantification are expected, with application to the presymptomatic phase of human disease offering the hope of prevention strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-1063-3277</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oeckl</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7652-7023</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (Dzne e.V.), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feneberg</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5404-7259</Identifier><AffiliationInfo><Affiliation>Departments of Neurology and Translational Neuroscience, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4273-4267</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Roman</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9715-5951</Identifier><AffiliationInfo><Affiliation>Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessler</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/T006927/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Proteomics</MedlineTA><NlmUniqueID>101223548</NlmUniqueID><ISSNLinking>1478-9450</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34758687</ArticleId><ArticleId IdType="doi">10.1080/14789450.2021.2004890</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>